<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35834042</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1076</ISSN><JournalIssue CitedMedium="Internet"><Volume>181</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>Sep</Month></PubDate></JournalIssue><Title>European journal of pediatrics</Title><ISOAbbreviation>Eur J Pediatr</ISOAbbreviation></Journal><ArticleTitle>Long-COVID in immunocompromised children.</ArticleTitle><Pagination><StartPage>3501</StartPage><EndPage>3509</EndPage><MedlinePgn>3501-3509</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00431-022-04561-1</ELocationID><Abstract><AbstractText Label="UNLABELLED">Coronavirus disease 2019 (COVID-19) can lead to an illness characterized by persistent symptoms which affect various organs and systems, known as long-COVID. This study aimed to assess the prevalence and clinical characteristics of long-COVID in children with immunodeficiency, in comparison to those without. A self-constructed questionnaire was created, which included questions regarding the child's general health, the course of their COVID-19, their symptoms of long-COVID and its impact on their daily functioning, the diagnosis of multisystem inflammatory syndrome (MIS-C), and vaccination status. The questionnaire was completed by parents of 147 children - 70 children with a diagnosis of immunodeficiency (47.6%) and 77 who were immunocompetent (52.4%). Immunocompetent children were more significantly affected by long-COVID than those immunocompromised. Its prevalence in the first 12-week post-infection was 60.0% and 35.7% in these groups, respectively. Beyond this period, these percentages had dropped to 34.6% and 11.43%, respectively. Children who were immunocompetent reported more often symptoms of fatigue, reduced exercise tolerance, and difficulty concentrating. Meanwhile, there was a slight increase in complaints of gastrointestinal symptoms in immunocompromised patients. The risk of developing long-COVID increased with age and COVID-19 severity in both groups. Furthermore, the daily activities of immunocompetent children were limited more frequently (41.8%) than for those who were immunocompromised (25%).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Although immunocompromised children experienced long-COVID, its prevalence and impact on daily functioning were significantly lower than among immunocompetent children. However, as the pathomechanisms of long-COVID are not yet fully understood, it is not currently possible to fully explain these findings.</AbstractText><AbstractText Label="WHAT IS KNOWN" NlmCategory="BACKGROUND">&#x2022; Long COVID is characterized by persistent symptoms following COVID-19, which can affect various tissues and organs, as well as mental health. &#x2022; Due to the similar course of COVID-19 - mainly mild or asymptomatic - among children with and without immunodeficiency, the question arises, over whether the prevalence and severity of long-COVID is also similar in both groups.</AbstractText><AbstractText Label="WHAT IS NEW" NlmCategory="BACKGROUND">&#x2022; Immunocompromised children also suffer from long-COVID, but the prevalence is significantly lower than in the immunocompetent group of children. &#x2022; The potential causes of less frequent and milder long-COVID in this group may be the milder course of COVID-19 and the state of reduced immunity protecting against neuroinflammation.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kuczborska</LastName><ForeName>Karolina</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-2644-5588</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, Nutrition and Metabolic Disorders, Children's Memorial Health Institute, Av. Dzieci Polskich 20, 04-730, Warsaw, Poland. k.kuczborska@ipczd.pl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buda</LastName><ForeName>Piotr</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-3891-4989</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, Nutrition and Metabolic Disorders, Children's Memorial Health Institute, Av. Dzieci Polskich 20, 04-730, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ksi&#x105;&#x17c;yk</LastName><ForeName>Janusz</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-9136-2722</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, Nutrition and Metabolic Disorders, Children's Memorial Health Institute, Av. Dzieci Polskich 20, 04-730, Warsaw, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur J Pediatr</MedlineTA><NlmUniqueID>7603873</NlmUniqueID><ISSNLinking>0340-6199</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Disease" UI="C000705967">pediatric multisystem inflammatory disease, COVID-19 related</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="Y">Coronavirus Infections</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016867" MajorTopicYN="N">Immunocompromised Host</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="Y">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018746" MajorTopicYN="N">Systemic Inflammatory Response Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Immunodeficiency</Keyword><Keyword MajorTopicYN="N">Long-COVID</Keyword><Keyword MajorTopicYN="N">Pediatric population</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>14</Day><Hour>11</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>7</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35834042</ArticleId><ArticleId IdType="pmc">PMC9281224</ArticleId><ArticleId IdType="doi">10.1007/s00431-022-04561-1</ArticleId><ArticleId IdType="pii">10.1007/s00431-022-04561-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cao Q, Chen YC, Chen CL, Chiu CH. SARS-CoV-2 infection in children: transmission dynamics and clinical characteristics. J Formos Med Assoc. 2020;119(3):670&#x2013;673. doi: 10.1016/j.jfma.2020.02.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jfma.2020.02.009</ArticleId><ArticleId IdType="pmc">PMC7126646</ArticleId><ArticleId IdType="pubmed">32139299</ArticleId></ArticleIdList></Reference><Reference><Citation>Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020;395(10237):1607&#x2013;1608. doi: 10.1016/S0140-6736(20)31094-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31094-1</ArticleId><ArticleId IdType="pmc">PMC7204765</ArticleId><ArticleId IdType="pubmed">32386565</ArticleId></ArticleIdList></Reference><Reference><Citation>NICE 2021 (2021)&#xa0;COVID-19 rapid guideline: managing the long-term effects of COVID-19. NICE Guideline 188. NICE. Available at:&#xa0;www.nice.org.uk/ng188</Citation><ArticleIdList><ArticleId IdType="pubmed">33555768</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuczborska K, Ksi&#x105;&#x17c;yk J (2021) Prevalence and course of SARS-CoV-2 infection among immunocompromised children hospitalised in the Tertiary Referral Hospital in Poland. J Clin Med 10(19):4556. 10.3390/jcm10194556</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8509507</ArticleId><ArticleId IdType="pubmed">34640570</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A, Bernabei R, Landi F (2020) Gemelli against COVID-19 post-acute care study group. Persistent symptoms in patients after acute COVID-19.&#xa0;JAMA 324(6):603&#x2013;605. 10.1001/jama.2020.12603</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludvigsson JF. Case report and systematic review suggest that children may experience similar long-term effects to adults after clinical COVID-19. Acta Paediatr. 2021;110(3):914&#x2013;921. doi: 10.1111/apa.15673.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apa.15673</ArticleId><ArticleId IdType="pmc">PMC7753397</ArticleId><ArticleId IdType="pubmed">33205450</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludvigsson JF. Reporting suspicions of long COVID in children is justified during this global emergency. Acta Paediatr. 2021;110(4):1373. doi: 10.1111/apa.15762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apa.15762</ArticleId><ArticleId IdType="pmc">PMC8013867</ArticleId><ArticleId IdType="pubmed">33459404</ArticleId></ArticleIdList></Reference><Reference><Citation>Buonsenso D, Munblit D, De Rose C, Sinatti D, Ricchiuto A, Carfi A, Valentini P. Preliminary evidence on long COVID in children. Acta Paediatr. 2021;110(7):2208&#x2013;2211. doi: 10.1111/apa.15870.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apa.15870</ArticleId><ArticleId IdType="pmc">PMC8251440</ArticleId><ArticleId IdType="pubmed">33835507</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmermann P, Pittet LF, Curtis N (2021) How common is Long COVID in children and adolescents? Pediatr Infect Dis J 40(12): e482-e487. 10.1097/INF.0000000000003328</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8575095</ArticleId><ArticleId IdType="pubmed">34870392</ArticleId></ArticleIdList></Reference><Reference><Citation>Molteni E, Sudre CH, Canas LS et al (2021) Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2 [published correction appears in Lancet Child Adolesc Health. 2021 31 August].&#xa0;Lancet Child Adolesc Health 5(10):708&#x2013;718. 10.1016/S2352-4642(21)00198-X</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8443448</ArticleId><ArticleId IdType="pubmed">34358472</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal AD, VanElzakker MB (2021) Long COVID or Post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms.&#xa0;Front Microbiol 12:698169. 10.3389/fmicb.2021.698169</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Lled&#xf3; GM, Sellares J, Brotons C et al (2022) Post-acute COVID-19 syndrome: a new tsunami requiring a universal case definition.&#xa0;Clin Microbiol Infect 28(3):315&#x2013;318. 10.1016/j.cmi.2021.11.015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8610558</ArticleId><ArticleId IdType="pubmed">34826619</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend L, Dyer AH, Jones K et al (2020) Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLoS One 15(11):e0240784. 10.1371/journal.pone.0240784</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7652254</ArticleId><ArticleId IdType="pubmed">33166287</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell ML, Catalfamo CJ, Farland LV, Ernst KC, Jacobs ET, Klimentidis YC, Jehn M, Pogreba-Brown K. Post-acute sequelae of COVID-19 in a non-hospitalized cohort: results from the Arizona CoVHORT. PLoS ONE. 2021;16(8):e0254347. doi: 10.1371/journal.pone.0254347.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0254347</ArticleId><ArticleId IdType="pmc">PMC8336814</ArticleId><ArticleId IdType="pubmed">34347785</ArticleId></ArticleIdList></Reference><Reference><Citation>Rai DK, Sharma P, Kumar R (2021) Post covid 19 pulmonary fibrosis. Is it real threat? Indian J Tuberc 68(3):330&#x2013;333. 10.1016/j.ijtb.2020.11.003</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7654356</ArticleId><ArticleId IdType="pubmed">34099197</ArticleId></ArticleIdList></Reference><Reference><Citation>Buonsenso D, Di Giuda D, Sigfrid L et al (2021) Evidence of lung perfusion defects and ongoing inflammation in an adolescent with post-acute sequelae of SARS-CoV-2 infection.&#xa0;Lancet Child Adolesc Health 5(9):677&#x2013;680. 10.1016/S2352-4642(21)00196-6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8324416</ArticleId><ArticleId IdType="pubmed">34339624</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Zhou L, Bao L et al (2021) SARS-CoV-2 crosses the blood-brain barrier accompanied with basement membrane disruption without tight junctions alteration. Signal Transduct Target Ther 6(1):337. 10.1038/s41392-021-00719-9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8419672</ArticleId><ArticleId IdType="pubmed">34489403</ArticleId></ArticleIdList></Reference><Reference><Citation>Welcome MO, Mastorakis NE. Neuropathophysiology of coronavirus disease 2019: neuroinflammation and blood brain barrier disruption are critical pathophysiological processes that contribute to the clinical symptoms of SARS-CoV-2 infection. Inflammopharmacology. 2021;29(4):939&#x2013;963. doi: 10.1007/s10787-021-00806-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10787-021-00806-x</ArticleId><ArticleId IdType="pmc">PMC8021940</ArticleId><ArticleId IdType="pubmed">33822324</ArticleId></ArticleIdList></Reference><Reference><Citation>Onofrio L, Caraglia M, Facchini G, Margherita V, De Placido S, Buonerba C (2020) Toll-like receptors and COVID-19: a two-faced story with an exciting ending. Future Sci OA 6(8):FSO605. 10.2144/fsoa-2020-0091</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7434222</ArticleId><ArticleId IdType="pubmed">32974046</ArticleId></ArticleIdList></Reference><Reference><Citation>Karnik M, Beeraka NM, Uthaiah CA, Nataraj SM, Bettadapura ADS, Aliev G, Madhunapantula SV. A review on SARS-CoV-2-induced neuroinflammation, neurodevelopmental complications, and recent updates on the vaccine development. Mol Neurobiol. 2021;58(9):4535&#x2013;4563. doi: 10.1007/s12035-021-02399-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-021-02399-6</ArticleId><ArticleId IdType="pmc">PMC8179092</ArticleId><ArticleId IdType="pubmed">34089508</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvey WT, Carabelli AM, Jackson B et al (2021) SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol 19(7):409&#x2013;424. 10.1038/s41579-021-00573-0</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8167834</ArticleId><ArticleId IdType="pubmed">34075212</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides TC (2022) Could SARS-CoV-2 spike protein be responsible for long-COVID syndrome?.&#xa0;Mol Neurobiol 59(3):1850&#x2013;1861. 10.1007/s12035-021-02696-0</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8757925</ArticleId><ArticleId IdType="pubmed">35028901</ArticleId></ArticleIdList></Reference><Reference><Citation>Afrin LB, Weinstock LB, Molderings GJ (2020) COVID-19 hyperinflammation and post-COVID-19 illness may be rooted in mast cell activation syndrome. Int J Infect Dis 100:327&#x2013;332. 10.1016/j.ijid.2020.09.016</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7529115</ArticleId><ArticleId IdType="pubmed">32920235</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J, Xiao J, Sun R et al (2020) Prolonged persistence of SARS-CoV-2 RNA in body fluids.&#xa0;Emerg Infect Dis 26(8):1834&#x2013;1838. 10.3201/eid2608.201097</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7392422</ArticleId><ArticleId IdType="pubmed">32383638</ArticleId></ArticleIdList></Reference><Reference><Citation>Vibholm LK, Nielsen SSF, Pahus MH et al (2021) SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses. EBioMedicine 64:103230. 10.1016/j.ebiom.2021.103230</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7847186</ArticleId><ArticleId IdType="pubmed">33530000</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi B, Choudhary MC, Regan J et al (2020) Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N Engl J Med 383(23):2291&#x2013;2293. 10.1056/NEJMc2031364</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7673303</ArticleId><ArticleId IdType="pubmed">33176080</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark SA, Clark LE, Pan J et al (2021) SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralisation escape mechanisms. Cell 184(10):2605&#x2013;2617. 10.1016/j.cell.2021.03.027</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7962548</ArticleId><ArticleId IdType="pubmed">33831372</ArticleId></ArticleIdList></Reference><Reference><Citation>Acharya D, Liu G, Gack MU (2020) Dysregulation of type I interferon responses in COVID-19. Nat Rev Immunol 20(7):397&#x2013;398. 10.1038/s41577-020-0346-x</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7249038</ArticleId><ArticleId IdType="pubmed">32457522</ArticleId></ArticleIdList></Reference><Reference><Citation>Drago F, Ciccarese G, Rebora A, Parodi A (2021) Human herpesvirus-6, -7, and Epstein-Barr virus reactivation in pityriasis rosea during COVID-19. J Med Virol 93(4):1850&#x2013;1851. 10.1002/jmv.26549</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7537064</ArticleId><ArticleId IdType="pubmed">32970319</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu R, Zhou Y, Cai L, Wang L, Han J, Yang X, Chen J, Chen J, Ma C, Shen L. Co-reactivation of the human herpesvirus alpha subfamily (herpes simplex virus-1 and varicella zoster virus) in a critically ill patient with COVID-19. Br J Dermatol. 2020;183(6):1145&#x2013;1147. doi: 10.1111/bjd.19484.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjd.19484</ArticleId><ArticleId IdType="pmc">PMC7436688</ArticleId><ArticleId IdType="pubmed">32790074</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T, Song J, Liu H, Zheng H, Chen C. Positive Epstein-Barr virus detection in coronavirus disease 2019 (COVID-19) patients. Sci Rep. 2021;11(1):10902. doi: 10.1038/s41598-021-90351-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-90351-y</ArticleId><ArticleId IdType="pmc">PMC8149409</ArticleId><ArticleId IdType="pubmed">34035353</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>